A pregnancy peptide tied to fetal heart defects

Pregnancy is full of screening tests, but congenital heart disease still often arrives as an ultrasound finding without a simple molecular explanation.

That’s part of why peptide biology can feel like magic when it lands in the pregnancy world. A single small signal that might predict or even influence development is an intoxicating idea.

A new study in Advanced Science argues that one such signal, ELABELA (ELA), may be a meaningful piece of the puzzle. The authors report that ELA levels were lower in human fetal cardiac tissue from congenital heart disease cases, and lower in maternal plasma in pregnancies affected by fetal congenital heart disease. In mouse models, they go further: deleting ELA in cardiac progenitor cells disrupted mitochondrial function and contributed to malformations, while giving exogenous ELA reduced congenital heart disease severity and incidence.

Paper: ELABELA Targets Mitochondria to Modulate Heart Development (DOI: https://doi.org/10.1002/advs.202506525).

What ELABELA is (in plain language)

ELABELA is an endogenous peptide that acts as a signal in development and physiology. In this paper, the authors focus on its role in the developing heart.

The headline idea is not “ELA is a cure.” It’s that ELA might be a regulatory signal that the fetal heart needs, and that low ELA might correlate with developmental risk.

What the study reports

The paper builds its claim across several layers.

In humans, the authors report that ELA levels were significantly reduced in fetal cardiac tissues with congenital heart disease, and that maternal plasma ELA levels were down-regulated in pregnancies with fetal congenital heart disease.

In mice, they report that deleting ELA in cardiac progenitor cells disrupted mitochondrial function and directly contributed to cardiac malformations.

They also propose a mechanistic pathway. In their model, ELA deficiency caused mitochondrial swelling through inhibiting the APJ-AKT-BCL2/BAX signaling pathway, linking a peptide signal to a specific “cell survival and mitochondria integrity” control layer.

Finally, they report that exogenous ELA administration reduced both congenital heart disease severity and incidence in mice.

Why this matters (and why it’s easy to overhype)

This is the kind of work that can matter even if it never becomes a product.

As a biomarker story, the short-term value would be: can ELA levels help identify higher-risk pregnancies earlier, or help stratify follow-up and imaging.

As a mechanism story, it suggests a specific node where development, mitochondrial health, and signaling intersect. That creates a testable hypothesis for other labs.

But the translation hurdles are non-trivial.

A plasma signal that differs “on average” is not automatically a useful clinical screen. You need performance characteristics, standardized assays, and an ethical workflow that answers a real question: what changes if we know.

And any idea that sounds like “preventing congenital heart disease during pregnancy” demands exceptional evidence and safety standards.

What we know vs what we don’t

What we know:

This paper reports reduced ELA in human congenital heart disease fetal tissue and in maternal plasma in affected pregnancies, plus mouse genetic and intervention evidence pointing to a mitochondria-related mechanism in cardiac development.

What we don’t know yet:

Whether ELA will replicate as a robust biomarker across populations.

Whether ELA measurements add predictive value beyond existing screening.

Whether any intervention concept is safe or feasible in humans.

What ELABELA is (in plain language)

What the study reports

Why this matters (and why it’s easy to overhype)

What we know vs what we don’t

Further reading

Related reading